Mawson Infrastructure Group Inc. — Director's Dealing 2019

Apr 24, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Wize Pharma, Inc. (WIZP)
CIK: 0001218683
Period of Report: 2019-04-21

Reporting Person: Danenberg Noam (Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-04-21	Common Stock	P	125000	$1.00	Acquired	165100	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-04-21	Convertible Loans	$1.1112	P	265531	Acquired	2019-05-31	Common Stock (265531)	Indirect
2019-04-21	Investment Rights	$1.332	P	94382	Acquired	2019-11-30	Common Stock (94382)	Indirect
2019-04-21	Series A Warrants	$1.10	P	125000	Acquired		Common Stock (125000)	Direct
2019-04-21	Series B Warrants	$1.00	P	125000	Acquired		Common Stock (125000)	Direct

Footnotes

F1: Issuable upon the conversion of the convertible loans under the January 19, 2017 Loan Agreement (the "Loan Agreement") by and among the Issuer and Ridge Valley Corporation, among others. The Convertible Loans may be converted at any time.

F2: Mr. Danenberg waived a debt owed to him by Ridge Valley Corporation as consideration for these derivative securities.

F3: Held by Mr. Danenberg's wholly-owned company Mobigo Inc.

F4: The Series A Warrants expire sixty (60) months after October 23, 2018.

F5: Purchased together with the 125,000 shares of Common Stock described in Table I for total purchase price of $125,000.

F6: The Series B Warrants expire twenty (20) days following the later of (i) the public announcement of Phase II clinical data for LO2A or (ii) six (6) months following October 23, 2018.